Log In Sign up
The largest database of trusted experimental protocols

Anti mouse pd 1

Manufactured by BioXCell
Visit Supplier
Sourced in United States

Anti-mouse PD-1 is a laboratory reagent used in immunological research. It is a monoclonal antibody that binds to the programmed cell death protein 1 (PD-1) expressed on the surface of mouse immune cells. This antibody can be used to modulate the PD-1 pathway, which is involved in the regulation of immune responses.

Automatically generated - may contain errors

Lab products found in correlation

Anti mouse ctla 4, by BioXCell (4 mentions) Sytox green, by Thermo Fisher Scientific (3 mentions) Tumor dissociation kit, by Miltenyi Biotec (2 mentions) Rat igg2a, by BioXCell (2 mentions) Degarelix, by Ferring (1 mentions) Clophosome, by Formumax Scientific (1 mentions) αcd38 pe cy7, by BioLegend (1 mentions) αcd8 fitc, by BioLegend (1 mentions) Dnase, by Roche (1 mentions) Liberase, by Roche (1 mentions) Invivomab anti mouse pd l1, by BioXCell (1 mentions) Matrigel matrix, by Corning (1 mentions) Avastin, by Roche (1 mentions) Anti mouse cd4, by BD (1 mentions) Mouse anti ki67, by Thermo Fisher Scientific (1 mentions) Anti mouse gr 1, by BioLegend (1 mentions) Anti mouse b220, by BioLegend (1 mentions) Anti mouse cd206, by BD (1 mentions) Anti human mouse granzyme b, by BioLegend (1 mentions) Anti mouse lag 3, by BD (1 mentions)

Close spelling variants of this product

Anti-PD-1 (65 citations) Anti-mouse PD-1 antibody (18 citations) Anti-mouse PD-1 (clone RMP1–14; (15 citations) InVivoMab anti-mouse PD-1 (CD279), (9 citations) InVivoMab anti-mouse PD-1 (8 citations) Anti-mouse PD-1 antibody (clone RMP1-14) (6 citations) InVivoPlus anti-mouse PD-1 (4 citations) Anti-mouse PD-1 MAb (4 citations) Anti-mouse PD-1 antibody (RMP1-14; (3 citations) Anti-mouse PD-1 (clone 29F.1A12, (3 citations)

13 protocols using anti mouse pd 1

1

Immune Checkpoint Inhibitor Therapy in Murine Tumor Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
InVivoMAb Anti-mouse PD-1 (10 mg/kg, clone J43, Bioxcell, West Lebanon, NH, USA), InVivoMAb anti-mouse CTLA-4 antibody (1 mg/kg, clone 9H10, Bioxcell), or InVivoMAb hamster anti-mouse IgG control antibodies (clone N/A, catalog # BE 0091, Bioxcell) were administered every other day for a total of four doses by intraperitoneal (i.p.) injection. The first dose was administered upon the larger tumors reaching 100 to 200 mm3, except for mice allocated to groups receiving androgen deprivation therapy in which case first dose was given 4 days after initiation of androgen deprivation therapy. When employed, androgen deprivation was induced by degarelix (Ferring Pharmaceuticals, Saint Prex, Switzerland), administered in single s.c. dose of 25 mg/kg upon the larger tumor graft reaching a volume of 300–400 mm3.
Benzon B., Glavaris S.A., Simons B.W., Hughes R.M., Ghabili K., Mullane P., Miller R., Nugent K., Shinder B., Tosoian J., Fuchs E.J., Tran P.T., Hurley P.J., Vuica-Ross M., Schaeffer E.M., Drake C.G, & Ross A.E. (2018). Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer. Prostate cancer and prostatic diseases, 21(1), 126-136.
+ Open protocol
+ Expand
2

Evaluating Anti-CD200R1 Adenovirus Therapy

Check if the same lab product or an alternative is used in the 5 most similar protocols
Female C57BL/6 mice and C57BL/6-Tg (Foxp3-GFP)90Pkraj/J (The Jackson Laboratory, Bar Harbor, ME, USA) of 6 to 8 weeks old were inoculated subcutaneously with 1 × 106 MEER/CD200High or MEER/control cells. When tumors were palpable (approximately day 10 to 13), 5 × 108 PFUs of adenovirus were injected intratumorally 3 times at 4-day intervals. Tumors were harvested from the mice after euthanasia, and tumor tissues were then dissociated using a tumor dissociation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). For macrophage depletion studies, 1.4 mg of a clodronate liposome formulation, Clophosome (FormuMax Scientific, Sunnyvale, CA, USA), was intraperitoneally injected before the first injection of adenovirus and was then administered (0.7 mg) every 4 days for a total of three treatments. For CD8+ T cell depletion studies, an anti-CD8 depletion antibody (clone 2.43) was injected intraperitoneally one day before virus injection and was then administered (500 μg) 6 times at 5-day intervals. For combination therapy of AdsCD200R1 with anti-PD1 antibodies, anti-mouse PD-1 (Bioxcell, Lebanon, NH, USA) was injected intraperitoneally (400 μg) 4 times at 4-day intervals. Tumor volumes were determined using the following formula: tumor volume (mm3) = length × width2 × 0.5236.
Shin S.P., Goh A.R., Ju J.M., Kang H.G., Kim S.J., Kim J.K., Park E.J., Bae Y.S., Choi K., Jung Y.S, & Lee S.J. (2021). Local adenoviral delivery of soluble CD200R-Ig enhances antitumor immunity by inhibiting CD200-β-catenin-driven M2 macrophage. Molecular Therapy Oncolytics, 23, 138-150.
+ Open protocol
+ Expand
3

Mouse MerTK-specific ASO for Immune Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
A mouse MerTK-specific ASO and control ASOs were produced by Ionis Pharmaceuticals, Inc. Anti-mouse CTLA-4 (Catalog# BP0164) and anti-mouse PD-1 (Catalog# BE0146) were purchased from BioXCell. Liberase (Catalog #05401127001) and DNAse (Catalog #4716728001) were purchased from Roche and Sigma-Aldrich, respectively. Flow cytometry antibodies, including αCD45-PerCP Cy5.5 (Catalog# 103131), αCD4-PE/Dazzle594 (Catalog# 100456), αCD8-FITC (Catalog# 100706), αGranzyme B (GrB)-Pacific Blue (Catalog# 515408), αGr1-BV510 (Catalog# 108437), αCD11b-APC Fire750 (Catalog# 101262), αF4/80-Alexa Fluor 700 (Catalog# 123130), αCD38-PE-Cy7 (Catalog# 102718), αCD206-PE (Catalog# 141706), and αMertK-APC (Catalog# 151507) were ordered from BioLegend.
Hu Y., Revenko A., Barsoumian H., Bertolet G., Fowlkes N.W., Maazi H., Green M.M., He K., Sezen D., Voss T.A., Leyton C.S., Masrorpour F., Rafiq Z., Puebla-Osorio N., Leuschner C., MacLeod R., Cortez M.A, & Welsh J.W. (2024). Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy. Journal of Experimental & Clinical Cancer Research : CR, 43, 70.
+ Open protocol
+ Expand
4

Xenograft Tumor Mouse Model for Avastin and Fc-VFD

Check if the same lab product or an alternative is used in the 5 most similar protocols
BALB/C Nu and C57BL/6JNarl mice were purchased from National Laboratory Animal Center (Taiwan). The mice were aged 5 weeks and weighed 18–21 g. The HCT15 cell sediment was rinsed twice with PBS and resuspended in PBS with Matrigel Matrix (Corning), with the cell concentration regulated to 1 × 106 /ml. Each mouse was injected subcutaneously at one side. After 1 week, when the tumors had grown to 50–100 mm3, the tumor-bearing nude mice were randomly divided into four groups (n = 6 per group) as follows: The control group (each mouse was intraperitoneally injected with 100 µl PBS twice a week, for a total of eight times); the Avastin group, Avastin (Roche, Basel, Switzerland) was intraperitoneally injected at different doses twice a week for a total of eight times; and the Fc-VFD group, Fc-VFD was intraperitoneally injected at different doses every other day, for a total of eight times. Starting from the first day of treatment, the tumor size was measured daily. For drugs combination experiments, B16/F10 mouse melanoma cancer cells (5 × 104 cells/ml) was injected subcutaneously into C57BL/6JNar mouse followed by the same treatment of drugs InViVoMab anti-mouse PD-L1 (BioXcell, SKU: BE0101), anti-mouse PD-1 (BioXcell, USA), and mouse IgG2b control (BioXcell, SKU: BE0090) by intraperitoneal injection stated above.
Kuo C.L., Chou H.Y., Lien H.W., Yeh C.A., Wang J.R., Chen C.H., Fan C.C., Hsu C.P., Kao T.Y., Ko T.M, & Lee A.Y. (2022). A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment. Cancer Immunology, Immunotherapy, 72(2), 351-369.
+ Open protocol
+ Expand
5

Tumor Immunotherapy Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Anti-mouse Tim-3 (clone: RMT3-23), anti-mouse PD-1 (clone: J43), anti-mouse Lag-3 (clone: C9B7W), Rat IgG isotype control (clone: 2A3) and polyclonal American hamster IgG were purchased from Bioxcell company for tumor therapy. For Flow cytometry, anti-mouse CD45 (clone: 30-F11), anti-mouse CD4 (clone: GK1.5), anti-mouse CD8a (clone: 53–6.7), anti-mouse Foxp3 (MF23), anti-mouse γδTCR (clone: GL3), anti-mouse CD103 (clone: M290), anti-mouse Tim-3 (clone: 5D12), anti-mouse Lag-3 (clone: C9B7W), anti-mouse Lag-3 (clone: C9B7W), anti-mouse CD206 (clone: MR5D3), anti-mouse CD62L (clone: MEL-14), anti-mouse CD44(clone: IM7), anti-mouse OX40 (OX-86), anti-mouse IL7R (clone: SB/199), anti-mouse GITR (clone:DTA-1) and anti-mouse CD11b (clone: M1/70) were purchased from BD Bioscience. anti-mouse Ki67(clone: SolA15), IFN-γ (clone: XMG1.2), CD11b (M1/70) were purchased from ebioscience. anti-mouse B220 (clone: RA3-6B2), anti-mouse CD8a (clone: 53–6.7), anti-human/mouse Granzyme B (clone: GB11), anti-mouse Granzyme A (clone: 3G8.5), anti-mouse MHC II (clone: M5/114.15.2), anti-mouse Gr-1 (clone: RB6-8C5), anti-mouse CD24 (clone: M1/69), anti-mouse F4/80 (clone: BM8) and anti-mouse NK1.1 (clone: PK136) were purchased from Biolegend. Mitotracker Deep Red FM labeling kit was purchased from Invitrogen. Ghost 510 and Zombie NIR dye was purchased from Tonbo Biosciences and Biolegend.
Yang M., Du W., Yi L., Wu S., He C., Zhai W., Yue C., Sun R., Menk A.V., Delgoffe G.M., Jiang J, & Lu B. (2020). Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment. Oncoimmunology, 9(1), 1708064.
+ Open protocol
+ Expand
6

Tumor Immunotherapy Combination Protocol

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
All DsiRNAs were synthesized by Integrated DNA Technologies (IDT, Coralville, IA). Primer and probe oligonucleotides used in real-time qPCR detection were synthesized by IDT or Life Technologies (Carlsbad, CA). Monoclonal antibodies (anti-mouse PD-1, anti-mouse CTLA-4, and anti-mouse CD8α) were purchased from Bio X Cell (Lebanon, NH). Tumor dissociation kit and Smart Strainers used to make single-cell suspension were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). Monoclonal antibodies used for flow cytometry were purchased from BioLegend (San Diego, CA). DCR-BCAT and Placebo LNPs were prepared as previously described.19 (link) Anti PD-1 antibody, anti-CTLA-4 antibodies, and anti-CD8a antibodies were diluted in PBS and administered intraperitoneally. DCR-BCAT and DCR-Placebo (LNP with chemistry-matched, scrambled CTNNB1 DsiRNA) were given intravenously. LGK-974 was purchased from Selleckchem.com (Houston, TX). LGK-974 was dissolved in DMSO (2%) and Corn Oil (solvents added individually and in order) and was administered orally.
Ganesh S., Shui X., Craig K.P., Park J., Wang W., Brown B.D, & Abrams M.T. (2018). RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade. Molecular Therapy, 26(11), 2567-2579.
+ Open protocol
+ Expand
7

Tumor Growth Inhibition by Immune Checkpoint Blockade

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
The tumor cell lines tested negative for mycoplasma infection and Plasmocin (InvivoGen) was used as a routine addition to the culture media to prevent mycoplasma contamination. The mice were inoculated with 1–1.5 × 105 B16F10-OVA cells or 2 × 106 MC38-OVA cells s.c. into the right flank. The mice were i.p. injected at the indicated time points with either 200 μg anti-PD-1 (29F1. A12, InVivoPlus anti-mouse PD-1, Bioxcell), anti-CTLA-4 (9H10, InVivoPlus anti-mouse CTLA-4, Bioxcell) or the respective isotype controls (anti-CTLA-4 isotype control, InVivoPlus polyclonal Syrian hamster IgG, Bioxcell; anti-PD-1 isotype control, InVivoPlus rat IgG2a isotype control, anti-trinitrophenol, Bioxcell). Tumor size was monitored every other day and tumors were harvested at the indicated time points for the analysis of tumor-infiltrating lymphocytes. Tumor volume was calculated as ½ × D × d2, where D is the major axis and d is the minor axis, as described previously45 (link). Tumor growth was monitored at least three times a week to ensure that the tumors did not exceed 25 mm in diameter.
Eschweiler S., Clarke J., Ramírez-Suástegui C., Panwar B., Madrigal A., Chee S.J., Karydis I., Woo E., Alzetani A., Elsheikh S., Hanley C.J., Thomas G.J., Friedmann P.S., Sanchez-Elsner T., Ay F., Ottensmeier C.H, & Vijayanand P. (2021). Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy. Nature immunology, 22(8), 1052-1063.
+ Open protocol
+ Expand
8

Interrogating Regulated Cell Death Pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies against MLKL (D6W1K) (#37705), MLKL (D2I6N) (#14993), Phospho-MLKL(Ser345) (D6E3G) (#37333), Phospho-MLKL(Ser358) (D6H3V) (#91689), RIP3 (E1Z1D) (#13526), XBP1 (E9V3E) (#40435), BIP (C50B12) (#3177), eIF2α (D7D3) (#5324), Phospho-eIF2α(Ser51) (D9G8) (#3398), Poly/Mono-ADP Ribose (E6F6A) (#83732), VDAC (D73D12) (#4866), GAPDH (14C10) (#2118) and β-Actin (13E5) (#4970) were purchased from Cell Signaling Technology. Anti-DFNA5/GSDME (#ab215191) and anti-AIF (#ab32516) were purchased from Abcam. Anti-Calnexin (#10427–1-AP) was purchased from Proteintech. Antibody against Histone H2A Rabbit mAb (#A3692) was purchased from ABClonal. Anti-mouse PD-1 (#BE0146) was purchased from BioXcell.
Sodium palmitate (#S161420) was purchased from Aladin. BSA (Fatty Acid & IgG Free) (#ST025) was purchased from Beyotime. Necrostatin-1 (#S8037), ferrostatin-1 (#S7243), Z-VAD-FMK (#S7023), Birinapant (#S7015), Olaparib (AZD2281) (#S1060), Ceapin-A7 (#E1099), GSK2606414 (#S7307), 4μ8C (HY-19707) (#S7272), and MNNG (#E0157) were obtained from Selleck Chemicals. SYTOX Green and Magnesium Green were purchased from Thermo Fisher Scientific. Recombinant murine and human TNF-α were purchased from Peprotech.
Jiang X., Deng W., Tao S., Tang Z., Chen Y., Tian M., Wang T., Tao C., Li Y., Fang Y., Pu C., Gao J., Wang X., Qu W., Gai X., Ding Z., Fu Y., Zheng Y., Cao S., Zhou J., Huang M., Liu W., Xu J., Fan J, & Shi Y. (2023). A RIPK3-independent role of MLKL in suppressing parthanatos promotes immune evasion in hepatocellular carcinoma. Cell Discovery, 9, 7.
+ Open protocol
+ Expand
9

Targeted Immune Depletion in Lung Cancer

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
For immune-checkpoint blockade therapy to the two-tumor models of LLC, 344SQ-P and 344SQ-R, a 200 μg/dose of anti-mouse-PD-1 (Bio X Cell, clone RMP1–14) in 250 μL sterile PBS was given intraperitoneally twice a week, beginning on the first day of radiation and continuing until death or experimental endpoint. Macrophage depletion to the two-tumor model of LLC was accomplished by alternating intraperitoneal/intratumor injections of 100 μg/dose of anti-mouse F4/80 (Bio X Cell, clone CI: A3–1) starting on day 5, for up to 10 days, and then twice a week thereafter [19 (link)]. CD8+ and CD4+ T cells to the LLC two-tumor model were depleted by intraperitoneally injected anti-CD8 (10mg/kg, CI:A3–1, BioXCell) and anti-CD4 (10mg/kg, clone GK 1.5, BioXCell) on day 5 and twice a week thereafter. Cellular depletion of macrophages, CD8+ T cells, and CD4+ T cells was confirmed by flow cytometry.
, & Doyle D.J. (2002). Errors of our ways. CMAJ: Canadian Medical Association Journal, 166(2), 221.
+ Open protocol
+ Expand
10

Formulation and Characterization of CGMP R-DOTAP Liposomal Nanoparticles

Check if the same lab product or an alternative is used in the 5 most similar protocols
Current good manufacturing practice–grade (CGMP) R-DOTAP was provided by Merck & Cie (Shaffhausen, Switzerland). CGMP R-DOTAP liposomal nanoparticles were produced by Evonik (Vancouver, Canada) according to protocols described previously (32 (link)). CGMP peptide Ags (Table I) were provided by AmbioPharm (North Augusta, SC). Research-grade synthetic peptide Ags were synthesized and purified to >95% purity by GenScript (Piscataway, NJ). Fluorochrome-conjugated mouse monoclonal anti-mouse CD3 (clone: 145-2c11), CD4 (clone: GK1.5), CD8 (clone: YTS165.7.7), NKP36 (clone: 29A1.4), CD11b (clone: M1/70), IFN-γ (clone: XMG1.2), TNF-α (clone: MP6-XT22), and IL-2 (clone: JES6.5H4), were purchased from BioLegend (San Diego, CA). Fluorochrome-conjugated anti-mouse CD69 (clone: H1-2F3) and anti-mouse CD11c (clone: HL3), were purchased from BD Biosciences (San Jose, CA). Fluorochrome-conjugated anti-mouse monoclonal Foxp3 (clone: FJK-16s) and CD25 (clone: PC61.5) were purchased from eBioscience (San Diego, CA). Allophycocyanin-labeled H2-Db E749–57 (RAHYNIVTF) loaded MHC class I dextramers were purchased from Immudex (Fairfax, VA). Anti-mouse PD-1 (clone: RMP1-14) was purchased from Bio X Cell (West Lebanon, NH).
Gandhapudi S.K., Ward M., Bush J.P., Bedu-Addo F., Conn G, & Woodward J.G. (2019). Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response. Journal of immunology (Baltimore, Md. : 1950), 202(12), 3524-3536.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!